However, recent single-cell sequencing methods that performed simultaneous mutation detection and transcriptome analysis showed that an ET patient acquired the JAK2 V617F mutation before a TET2 mutation, while an MPN patient exhibiting bone marrow fibrosis a TET2 mutation before the JAK2 V617F mutation [31, 32]. This evidence concerns the gene JAK2 and myeloproliferative disorder.